Cipla: Omeprazole disappointment - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Cipla: Omeprazole disappointment

Oct 14, 2002

In a big disappointment for Cipla, Andrx the US partner of the company has lost its patent challenge for generic Omeprazole (Prilosec). The US district court has ruled that Andrx infringes the original patent of AstraZeneca. Since Cipla was expected to supply a major part of Andrx’s raw material requirement for Omeprazole, market participants were expecting major revenues from this bulk exports. The court has concluded that two other companies, Merck and Dr Reddy's also infringe these patents. The ruling means that Andrx would not be able to launch generic Prilosec (Omeprazole) in the US market in near future.

It may be recalled that Dr. Reddy’s lost on its 180-day marketing exclusivity claim for Omeprazole in Nov’01. Consequently, Andrx gained from the withdrawal of tentative approval of Dr. Reddy’s. Cipla has a tie-up with Andrx to supply bulk Omeprazole. Omeprazole (an anti-ulcerant product) is the largest selling pharma product in the world with US sales in excess of US$ 4 bn. However, Andrx could not launch the product immediately, as the issue was caught in a legal tangle. Astra Zeneca, the original patent holder claims that the makers of the generic version are violating patents that have not yet expired.

Cipla had already started supplying sample quantities on account of stocking exercise carried out by Andrx and other huge consignments where expected to follow. Given the situation now, it would be safe to assume that there would be no more supply of Omeprazole to Andrx. However, the impact of quantities already supplied cannot be judged currently.

Our EPS estimates for Cipla factors in Rs 850 m revenues (almost 5% of total revenues FY03E) in the current year from Omeprazole exports. We would be soon downgrading our EPS estimates for Cipla for the current year on the back of this development. On the other hand, we maintain our profitability estimates for Dr. Reddy’s (Rs 61 - EPS for FY03) as we had not included any revenues from Omeprazole on account of prevailing uncertainty.


Equitymaster requests your view! Post a comment on "Cipla: Omeprazole disappointment". Click here!

  

More Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 18, 2020 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS